Harvey Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-20,500
| Closed | -$544K | – | 83 |
|
|
2024
Q4 | $544K | Buy |
+20,500
| New | +$556K | 0.13% | 65 |
|
|
2024
Q3 | – | Sell |
-28,800
| Closed | -$806K | – | 80 |
|
|
2024
Q2 | $806K | Sell |
28,800
-5,750
| -17% | -$158K | 0.21% | 57 |
|
|
2024
Q1 | $959K | Sell |
34,550
-5,400
| -14% | -$150K | 0.28% | 53 |
|
|
2023
Q4 | $1.15M | Sell |
39,950
-25,110
| -39% | -$759K | 0.38% | 49 |
|
|
2023
Q3 | $2.16M | Sell |
65,060
-2,400
| -4% | -$84.9K | 0.76% | 38 |
|
|
2023
Q2 | $2.47M | Buy |
67,460
+51,660
| +327% | +$2.01M | 0.91% | 32 |
|
|
2023
Q1 | $645K | Buy |
15,800
+8,800
| +126% | +$380K | 0.25% | 54 |
|
|
2022
Q4 | $359K | Hold |
7,000
| – | – | 0.15% | 66 |
|
|
2022
Q3 | $306K | Hold |
7,000
| – | – | 0.13% | 66 |
|
|
2022
Q2 | $367K | Hold |
7,000
| – | – | 0.14% | 65 |
|
|
2022
Q1 | $362K | Hold |
7,000
| – | – | 0.11% | 64 |
|
|
2021
Q4 | $413K | Buy |
7,000
+2,000
| +40% | +$99.1K | 0.13% | 65 |
|
|
2021
Q3 | $215K | Buy |
+5,000
| New | +$222K | 0.07% | 76 |
|
|
2020
Q4 | – | Sell |
-8,432
| Closed | -$293K | – | 79 |
|
|
2020
Q3 | $293K | Buy |
+8,432
| New | +$296K | 0.13% | 66 |
|
|
2019
Q3 | – | Sell |
-5,270
| Closed | -$216K | – | 78 |
|
|
2019
Q2 | $216K | Hold |
5,270
| – | – | 0.1% | 75 |
|
|
2019
Q1 | $212K | Hold |
5,270
| – | – | 0.1% | 74 |
|
|
2018
Q4 | $218K | Sell |
5,270
-1,054
| -17% | -$43.8K | 0.12% | 72 |
|
|
2018
Q3 | $264K | Sell |
6,324
-12,648
| -67% | -$487K | 0.11% | 72 |
|
|
2018
Q2 | $653K | Hold |
18,972
| – | – | 0.26% | 58 |
|
|
2018
Q1 | $638K | Sell |
18,972
-316
| -2% | -$10.9K | 0.24% | 61 |
|
|
2017
Q4 | $662K | Sell |
19,288
-264
| -1% | -$9K | 0.24% | 61 |
|
|
2017
Q3 | $662K | Sell |
19,552
-5,797
| -23% | -$186K | 0.27% | 52 |
|
|
2017
Q2 | $807K | Hold |
25,349
| – | – | 0.35% | 50 |
|
|
2017
Q1 | $822K | Sell |
25,349
-117,099
| -82% | -$3.69M | 0.37% | 49 |
|
|
2016
Q4 | $4.39M | Buy |
142,448
+131,908
| +1,251% | +$4.03M | 2.04% | 18 |
|
|
2016
Q3 | $338K | Hold |
10,540
| – | – | 0.1% | 61 |
|
|
2016
Q2 | $352K | Hold |
10,540
| – | – | 0.18% | 59 |
|
|
2016
Q1 | $296K | Hold |
10,540
| – | – | 0.14% | 61 |
|
|
2015
Q4 | $322K | Hold |
10,540
| – | – | 0.13% | 68 |
|
|
2015
Q3 | $314K | Hold |
10,540
| – | – | 0.13% | 69 |
|
|
2015
Q2 | $333K | Hold |
10,540
| – | – | 0.11% | 72 |
|
|
2015
Q1 | $347K | Buy |
+10,540
| New | +$335K | 0.13% | 65 |
|
Other funds holding PFE
TIM
Harvey Capital Management's PFE Position: Q1 2025 in Review
Harvey Capital Management sold out of Pfizer (PFE) in Q1 2025, closing a stake of 20,500 shares — an estimated $544K sold.
Harvey Capital Management first reported a position in PFE in Q1 2015 and held it in 32 quarters. The position peaked at $4.39M in Q4 2016. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.
- Harvey Capital Management reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
- Harvey Capital Management sold 20,500 Pfizer shares in Q1 2025, an estimated $544K.
- Harvey Capital Management first reported a position in Pfizer in Q1 2015 and held it in 32 quarters.
- Harvey Capital Management's Pfizer position peaked at $4.39M in Q4 2016.
- 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.
Based on Harvey Capital Management's 13F filing for Q1 2025, filed 30 Apr 2025.